

**Texas Prior Authorization Program
Clinical Edit Criteria**

Drug/Drug Class

**Attention Deficit Disorder (ADD) / Attention
Deficit Hyperactivity Disorder (ADHD)
Medications**

This edit was recommended for review by an MCO with the support of the Office of the Medical Director. Texas DFPS updated their dosing guidelines in March 2016.

Clinical Edit Information Included in this Document

IR Formulations

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical edit
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical edit criteria rules
- **Logic diagram:** a visual depiction of the clinical edit criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes)
- **References:** clinical publications and sources relevant to this clinical edit

ER Formulations

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical edit
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical edit criteria rules
- **Logic diagram:** a visual depiction of the clinical edit criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes)
- **References:** clinical publications and sources relevant to this clinical edit

Non-stimulant Formulations (Except Clonidine ER)

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical edit
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical edit criteria rules
- **Logic diagram:** a visual depiction of the clinical edit criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes)
- **References:** clinical publications and sources relevant to this clinical edit

Clonidine ER

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical edit
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical edit criteria rules
- **Logic diagram:** a visual depiction of the clinical edit criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes)
- **References:** clinical publications and sources relevant to this clinical edit

Note: Click the hyperlink to navigate directly to that section.

Revision Notes

- Updated TX DFPS Recommended Dosing Tables, page 21 and 34



Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD)

IR Formulations Drugs Requiring Prior Authorization

Drug Requiring Prior Authorization	
Label Name	GCN
ADDERALL 10MG TABLET	56971
ADDERALL 12.5MG TABLET	29008
ADDERALL 15MG TABLET	29009
ADDERALL 20MG TABLET	56973
ADDERALL 30MG TABLET	56972
ADDERALL 5MG TABLET	56970
ADDERALL 7.5MG TABLET	29007
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG TABLET	56971
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 12.5MG TABLET	29008
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG TABLET	29009
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG TABLET	56973
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG TABLET	56972
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG TABLET	56970
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 7.5MG TABLET	29007
DESOXYN 5MG TABLET	19932
DEXMETHYLPHENIDATE 10MG TABLET	14975
DEXMETHYLPHENIDATE 2.5MG TABLET	14973
DEXMETHYLPHENIDATE 5MG TABLET	14974
DEXTROAMPHETAMINE 10MG TABLET	19880
DEXTROAMPHETAMINE 5MG TABLET	19881
DEXTROAMPHETAMINE 5MG/5ML SOLUTION	99801
EVEKEO 10MG TABLET	19821
EVEKEO 5MG TABLET	19822
FOCALIN 10MG TABLET	14975
FOCALIN 2.5MG TABLET	14973
FOCALIN 5MG TABLET	14974

Drug Requiring Prior Authorization	
Label Name	GCN
METHAMPHETAMINE 5MG TABLET	19932
METHYLIN 10MG CHEWABLE TABLET	22684
METHYLIN 10MG/5ML SOLUTION	22686
METHYLIN 2.5MG CHEWABLE TABLET	22682
METHYLIN 5MG CHEWABLE TABLET	22683
METHYLIN 5MG/5ML SOLUTION	22685
METHYLPHENIDATE 10 MG CHEW TB	22684
METHYLPHENIDATE 10MG TABLET	15911
METHYLPHENIDATE 10MG/5ML SOL	22686
METHYLPHENIDATE 2.5 MG CHEW TB	22682
METHYLPHENIDATE 20MG TABLET	15920
METHYLPHENIDATE 5 MG CHEW TB	22683
METHYLPHENIDATE 5MG TABLET	15913
METHYLPHENIDATE 5MG/5ML SOL	22685
PROCENTRA 5MG/5ML SOLUTION	99801
RITALIN 10MG TABLET	15911
RITALIN 20MG TABLET	15920
RITALIN 5MG TABLET	15913
ZENZEDI 10MG TABLET	19880
ZENZEDI 15MG TABLET	19885
ZENZEDI 2.5MG TABLET	34734
ZENZEDI 20MG TABLET	36463
ZENZEDI 30MG TABLET	36464
ZENZEDI 5MG TABLET	19881
ZENZEDI 7.5MG TABLET	34735



Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD)

IR Formulations Clinical Edit Criteria Logic


1. Is the client less than (<) 3 years of age?
 Yes – Deny
 No – Go to #2
2. Does the client have a history of substance abuse in the last 365 days?
 Yes – Deny
 No – Go to #3
3. Is the request for greater than (>) the Texas Department of Family and Protective Services (DFPS) maximum recommended daily dose?
 Yes – Deny
 No – Go to #4
4. Does the client have a paid claim for another IR stimulant in the past 14 days?
 Yes – Deny
 No – Go to #5
5. Is the client less than (<) 6 years of age?
 Yes – Go to #6
 No – Go to #7
6. Is the request for amphetamine salts, dextroamphetamine, dexamethylphenidate, methylphenidate, Procentra, or Zenzedi?
 Yes – Approve (365 days)
 No – Deny
7. Is the client greater than or equal to (\geq) 19 years of age?
 Yes – Go to #8
 No – Approve (365 days)
8. Does the client have a diagnosis of ADD/ADHD in the last 730 days?
 Yes – Approve (365 days)
 No – Go to #9
9. Does the client have a diagnosis of narcolepsy in the past 730 days?
 Yes – Go to #10
 No – Deny
10. Is the request for dexamethylphenidate or methamphetamine?
 Yes – Deny
 No – Approve (365 days)



**Attention Deficit Disorder (ADD) /
Attention Deficit Hyperactivity Disorder
(ADHD)**

**IR Formulations
Clinical Edit Criteria Logic Diagram**

The IR Formulations Clinical Edit Criteria Logic Diagram is shown on the following page.





Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD)

IR Formulations

Clinical Edit Criteria Supporting Tables

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
ICD-9 Code	Description
30400	OPIOID DEPENDENCE-UNSPEC
30401	OPIOID DEPENDENCE-CONTIN
30402	OPIOID DEPENDENCE-EPISOD
30403	OPIOID DEPENDENCE-REMISS
30410	SEDATIVE,HYPNOTIC OR ANXIOLYTIC DEPENDENCE UNSPECIFIED
30411	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, CONTINUOUS
30412	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, EPISODIC
30413	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION
30420	COCAINE DEPEND-UNSPEC
30421	COCAINE DEPEND-CONTIN
30422	COCAINE DEPEND-EPISODIC
30423	COCAINE DEPEND-REMISS
30430	CANNABIS DEPEND-UNSPEC
30431	CANNABIS DEPEND-CONTIN
30432	CANNABIS DEPEND-EPISODIC
30433	CANNABIS DEPEND-REMISS
30440	AMPHETAMIN DEPEND-UNSPEC
30441	AMPHETAMIN DEPEND-CONTIN
30442	AMPHETAMIN DEPEND-EPISOD
30443	AMPHETAMIN DEPEND-REMISS
30450	HALLUCINOGEN DEP-UNSPEC
30451	HALLUCINOGEN DEP-CONTIN
30452	HALLUCINOGEN DEP-EPISOD
30453	HALLUCINOGEN DEP-REMISS
30460	DRUG DEPEND NEC-UNSPEC
30461	DRUG DEPEND NEC-CONTIN
30462	DRUG DEPEND NEC-EPISODIC

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
30463	DRUG DEPEND NEC-IN REM
30470	OPIOID/OTHER DEP-UNSPEC
30471	OPIOID/OTHER DEP-CONTIN
30472	OPIOID/OTHER DEP-EPISOD
30473	OPIOID/OTHER DEP-REMISS
30480	COMB DRUG DEP NEC-UNSPEC
30481	COMB DRUG DEP NEC-CONTIN
30482	COMB DRUG DEP NEC-EPISOD
30483	COMB DRUG DEP NEC-REMISS
30490	DRUG DEPEND NOS-UNSPEC
30491	DRUG DEPEND NOS-CONTIN
30492	DRUG DEPEND NOS-EPISODIC
30493	DRUG DEPEND NOS-REMISS
30500	ALCOHOL ABUSE-UNSPEC
30501	ALCOHOL ABUSE-CONTINUOUS
30502	ALCOHOL ABUSE-EPISODIC
30503	ALCOHOL ABUSE-IN REMISS
30520	CANNABIS ABUSE-UNSPEC
30521	CANNABIS ABUSE-CONTIN
30522	CANNABIS ABUSE-EPISODIC
30523	CANNABIS ABUSE-IN REMISS
30530	HALLUCINOGEN ABUSE-UNSPEC
30531	HALLUCINOGEN ABUSE-CONTIN
30532	HALLUCINOGEN ABUSE-EPISOD
30533	HALLUCINOGEN ABUSE-REMISS
30540	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, UNSPECIFIED
30541	SEDATIVE, HYPNOTIC OR ANXIOLYTIC, ABUSE, CONTINUOUS
30542	SEDATIVE, HYPNOTIC, OR ANXIOLYTIC ABUSE, EPISODIC
30543	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, IN REMISSION
30550	OPIOID ABUSE-UNSPEC
30551	OPIOID ABUSE-CONTINUOUS
30552	OPIOID ABUSE-EPISODIC
30553	OPIOID ABUSE-IN REMISS
30560	COCAINE ABUSE-UNSPEC
30561	COCAINE ABUSE-CONTINUOUS
30562	COCAINE ABUSE-EPISODIC

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
30563	COCAINE ABUSE-IN REMISS
30570	AMPHETAMINE ABUSE-UNSPEC
30571	AMPHETAMINE ABUSE-CONTIN
30572	AMPHETAMINE ABUSE-EPISOD
30573	AMPHETAMINE ABUSE-REMISS
30590	DRUG ABUSE NEC-UNSPEC
30591	DRUG ABUSE NEC-CONTIN
30592	DRUG ABUSE NEC-EPISODIC
30593	DRUG ABUSE NEC-IN REMISS
ICD-10 Code	Description
F1010	ALCOHOL ABUSE UNCOMPLICATED
F10120	ALCOHOL ABUSE WITH INTOXICATION UNCOMPLICATED
F10121	ALCOHOL ABUSE WITH INTOXICATION DELIRIUM
F10129	ALCOHOL ABUSE WITH INTOXICATION UNSPECIFIED
F1014	ALCOHOL ABUSE WITH ALCOHOL-INDUCED MOOD DISORDER
F10150	ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F10151	ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F10159	ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F10180	ALCOHOL ABUSE WITH ALCOHOL-INDUCED ANXIETY DISORDER
F10181	ALCOHOL ABUSE WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION
F10182	ALCOHOL ABUSE WITH ALCOHOL-INDUCED SLEEP DISORDER
F10188	ALCOHOL ABUSE WITH OTHER ALCOHOL-INDUCED DISORDER
F1019	ALCOHOL ABUSE WITH UNSPECIFIED ALCOHOL-INDUCED DISORDER
F1020	ALCOHOL DEPENDENCE UNCOMPLICATED
F10220	ALCOHOL DEPENDENCE WITH INTOXICATION UNCOMPLICATED
F10221	ALCOHOL DEPENDENCE WITH INTOXICATION DELIRIUM
F10229	ALCOHOL DEPENDENCE WITH INTOXICATION UNSPECIFIED
F10230	ALCOHOL DEPENDENCE WITH WITHDRAWAL UNCOMPLICATED
F10231	ALCOHOL DEPENDENCE WITH WITHDRAWAL DELIRIUM
F10232	ALCOHOL DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE
F10239	ALCOHOL DEPENDENCE WITH WITHDRAWAL UNSPECIFIED
F1024	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED MOOD DISORDER

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F10250	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F10251	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F10259	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F1026	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING AMNESTIC DISORDER
F1027	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING DEMENTIA
F10280	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED ANXIETY DISORDER
F10281	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION
F10282	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SLEEP DISORDER
F10288	ALCOHOL DEPENDENCE WITH OTHER ALCOHOL-INDUCED DISORDER
F1029	ALCOHOL DEPENDENCE WITH UNSPECIFIED ALCOHOL-INDUCED DISORDER
F1110	OPIOID ABUSE UNCOMPLICATED
F11120	OPIOID ABUSE WITH INTOXICATION UNCOMPLICATED
F11121	OPIOID ABUSE WITH INTOXICATION DELIRIUM
F11122	OPIOID ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F11129	OPIOID ABUSE WITH INTOXICATION UNSPECIFIED
F1114	OPIOID ABUSE WITH OPIOID-INDUCED MOOD DISORDER
F11150	OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F11151	OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F11159	OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F11181	OPIOID ABUSE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION
F11182	OPIOID ABUSE WITH OPIOID-INDUCED SLEEP DISORDER
F11188	OPIOID ABUSE WITH OTHER OPIOID-INDUCED DISORDER
F1119	OPIOID ABUSE WITH UNSPECIFIED OPIOID-INDUCED DISORDER
F1120	OPIOID DEPENDENCE, UNCOMPLICATED
F1121	OPIOID DEPENDENCE, IN REMISSION
F11220	OPIOID DEPENDENCE WITH INTOXICATION UNCOMPLICATED
F11221	OPIOID DEPENDENCE WITH INTOXICATION DELIRIUM

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F11222	OPIOID DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F11229	OPIOID DEPENDENCE WITH INTOXICATION UNSPECIFIED
F1123	OPIOID DEPENDENCE WITH WITHDRAWAL
F1124	OPIOID DEPENDENCE WITH OPIOID-INDUCED MOOD DISORDER
F11250	OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F11251	OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F11259	OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F11281	OPIOID DEPENDENCE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION
F11282	OPIOID DEPENDENCE WITH OPIOID-INDUCED SLEEP DISORDER
F11288	OPIOID DEPENDENCE WITH OTHER OPIOID-INDUCED DISORDER
F1129	OPIOID DEPENDENCE WITH UNSPECIFIED OPIOID-INDUCED DISORDER
F1210	CANNABIS ABUSE UNCOMPLICATED
F12120	CANNABIS ABUSE WITH INTOXICATION UNCOMPLICATED
F12121	CANNABIS ABUSE WITH INTOXICATION DELIRIUM
F12122	CANNABIS ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F12129	CANNABIS ABUSE WITH INTOXICATION UNSPECIFIED
F12150	CANNABIS ABUSE WITH PSYCHOTIC DISORDER WITH DELUSIONS
F12151	CANNABIS ABUSE WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS
F12159	CANNABIS ABUSE WITH PSYCHOTIC DISORDER UNSPECIFIED
F12180	CANNABIS ABUSE WITH CANNABIS-INDUCED ANXIETY DISORDER
F12188	CANNABIS ABUSE WITH OTHER CANNABIS-INDUCED DISORDER
F1219	CANNABIS ABUSE WITH UNSPECIFIED CANNABIS-INDUCED DISORDER
F1220	CANNABIS DEPENDENCE, UNCOMPLICATED
F1221	CANNABIS DEPENDENCE, IN REMISSION
F12220	CANNABIS DEPENDENCE WITH INTOXICATION UNCOMPLICATED
F12221	CANNABIS DEPENDENCE WITH INTOXICATION DELIRIUM
F12222	CANNABIS DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F12229	CANNABIS DEPENDENCE WITH INTOXICATION UNSPECIFIED
F12250	CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH DELUSIONS

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F12251	CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS
F12259	CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER UNSPECIFIED
F12280	CANNABIS DEPENDENCE WITH CANNABIS-INDUCED ANXIETY DISORDER
F12288	CANNABIS DEPENDENCE WITH OTHER CANNABIS-INDUCED DISORDER
F1229	CANNABIS DEPENDENCE WITH UNSPECIFIED CANNABIS-INDUCED DISORDER
F1310	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, UNCOMPLICATED
F13120	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION UNCOMPLICATED
F13121	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION DELIRIUM
F13129	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION UNSPECIFIED
F1314	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER
F13150	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F13151	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F13159	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F13180	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER
F13181	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION
F13182	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER
F13188	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER
F1319	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER
F1320	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE UNCOMPLICATED
F1321	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE IN REMISSION
F13220	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION UNCOMPLICATED
F13221	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION DELIRIUM

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F13229	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION, UNSPECIFIED
F13230	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL UNCOMPLICATED
F13231	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL DELIRIUM
F13232	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE
F13239	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL UNSPECIFIED
F1324	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER
F13250	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER UNCOMPLICATED
F13251	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F13259	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F1326	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING AMNESTIC DISORDER
F1327	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PERSISTING DEMENTIA
F13280	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER
F13281	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION
F13282	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER
F13288	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER
F1329	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER
F1410	COCAINE ABUSE UNCOMPLICATED
F14120	COCAINE ABUSE WITH INTOXICATION UNCOMPLICATED
F14121	COCAINE ABUSE WITH INTOXICATION WITH DELIRIUM
F14122	COCAINE ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F14129	COCAINE ABUSE WITH INTOXICATION UNSPECIFIED
F1414	COCAINE ABUSE WITH COCAINE-INDUCED MOOD DISORDER
F14150	COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F14151	COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F14159	COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F14180	COCAINE ABUSE WITH COCAINE-INDUCED ANXIETY DISORDER
F14181	COCAINE ABUSE WITH COCAINE-INDUCED SEXUAL DYSFUNCTION
F14182	COCAINE ABUSE WITH COCAINE-INDUCED SLEEP DISORDER
F14188	COCAINE ABUSE WITH OTHER COCAINE-INDUCED DISORDER
F1419	COCAINE ABUSE WITH UNSPECIFIED COCAINE-INDUCED DISORDER
F1420	COCAINE DEPENDENCE UNCOMPLICATED
F14220	COCAINE DEPENDENCE WITH INTOXICATION UNCOMPLICATED
F14221	COCAINE DEPENDENCE WITH INTOXICATION DELIRIUM
F14222	COCAINE DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F14229	COCAINE DEPENDENCE WITH INTOXICATION UNSPECIFIED
F1423	COCAINE DEPENDENCE WITH WITHDRAWAL
F1424	COCAINE DEPENDENCE WITH COCAINE-INDUCED MOOD DISORDER
F14250	COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F14251	COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F14259	COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F14280	COCAINE DEPENDENCE WITH COCAINE-INDUCED ANXIETY DISORDER
F14281	COCAINE DEPENDENCE WITH COCAINE-INDUCED SEXUAL DYSFUNCTION
F14282	COCAINE DEPENDENCE WITH COCAINE-INDUCED SLEEP DISORDER
F14288	COCAINE DEPENDENCE WITH OTHER COCAINE-INDUCED DISORDER
F1429	COCAINE DEPENDENCE WITH UNSPECIFIED COCAINE-INDUCED DISORDER
F1510	OTHER STIMULANT ABUSE UNCOMPLICATED
F15120	OTHER STIMULANT ABUSE WITH INTOXICATION UNCOMPLICATED
F15121	OTHER STIMULANT ABUSE WITH INTOXICATION DELIRIUM
F15122	OTHER STIMULANT ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F15129	OTHER STIMULANT ABUSE WITH INTOXICATION UNSPECIFIED
F1514	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED MOOD DISORDER
F15150	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F15151	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F15159	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F15180	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED ANXIETY DISORDER
F15181	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION
F15182	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED SLEEP DISORDER
F15188	OTHER STIMULANT ABUSE WITH OTHER STIMULANT-INDUCED DISORDER
F1519	OTHER STIMULANT ABUSE WITH UNSPECIFIED STIMULANT-INDUCED DISORDER
F1520	OTHER STIMULANT DEPENDENCE UNCOMPLICATED
F15220	OTHER STIMULANT DEPENDENCE WITH INTOXICATION UNCOMPLICATED
F15221	OTHER STIMULANT DEPENDENCE WITH INTOXICATION DELIRIUM
F15222	OTHER STIMULANT DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F15229	OTHER STIMULANT DEPENDENCE WITH INTOXICATION UNSPECIFIED
F1523	OTHER STIMULANT DEPENDENCE WITH WITHDRAWAL
F1524	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED MOOD DISORDER
F15250	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F15251	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F15259	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F15280	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED ANXIETY DISORDER
F15281	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION
F15282	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED SLEEP DISORDER
F15288	OTHER STIMULANT DEPENDENCE WITH OTHER STIMULANT-INDUCED DISORDER

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F1529	OTHER STIMULANT DEPENDENCE WITH UNSPECIFIED STIMULANT-INDUCED DISORDER
F1610	HALLUCINOGEN ABUSE UNCOMPLICATED
F16120	HALLUCINOGEN ABUSE WITH INTOXICATION UNCOMPLICATED
F16121	HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM
F16122	HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F16129	HALLUCINOGEN ABUSE WITH INTOXICATION UNSPECIFIED
F1614	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER
F16150	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F16151	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F16159	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F16180	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER
F16183	HALLUCINOGEN ABUSE WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER (FLASHBACKS)
F16188	HALLUCINOGEN ABUSE WITH OTHER HALLUCINOGEN-INDUCED DISORDER
F1619	HALLUCINOGEN ABUSE WITH UNSPECIFIED HALLUCINOGEN-INDUCED DISORDER
F1620	HALLUCINOGEN DEPENDENCE UNCOMPLICATED
F16220	HALLUCINOGEN DEPENDENCE WITH INTOXICATION UNCOMPLICATED
F16221	HALLUCINOGEN DEPENDENCE WITH INTOXICATION WITH DELIRIUM
F16229	HALLUCINOGEN DEPENDENCE WITH INTOXICATION UNSPECIFIED
F1624	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED MOOD DISORDER
F16250	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F16251	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F16259	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F16280	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER
F16283	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER (FLASHBACKS)
F16288	HALLUCINOGEN DEPENDENCE WITH OTHER HALLUCINOGEN-INDUCED DISORDER

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F1629	HALLUCINOGEN DEPENDENCE WITH UNSPECIFIED HALLUCINOGEN-INDUCED DISORDER
F1810	INHALANT ABUSE UNCOMPLICATED
F18120	INHALANT ABUSE WITH INTOXICATION UNCOMPLICATED
F18121	INHALANT ABUSE WITH INTOXICATION DELIRIUM
F18129	INHALANT ABUSE WITH INTOXICATION UNSPECIFIED
F1814	INHALANT ABUSE WITH INHALANT-INDUCED MOOD DISORDER
F18150	INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F18151	INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F18159	INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F1817	INHALANT ABUSE WITH INHALANT-INDUCED DEMENTIA
F18180	INHALANT ABUSE WITH INHALANT-INDUCED ANXIETY DISORDER
F18188	INHALANT ABUSE WITH OTHER INHALANT-INDUCED DISORDER
F1819	INHALANT ABUSE WITH UNSPECIFIED INHALANT-INDUCED DISORDER
F1820	INHALANT DEPENDENCE, UNCOMPLICATED
F18220	INHALANT DEPENDENCE WITH INTOXICATION UNCOMPLICATED
F18221	INHALANT DEPENDENCE WITH INTOXICATION DELIRIUM
F18229	INHALANT DEPENDENCE WITH INTOXICATION UNSPECIFIED
F1824	INHALANT DEPENDENCE WITH INHALANT-INDUCED MOOD DISORDER
F18250	INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F18251	INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F18259	INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F1827	INHALANT DEPENDENCE WITH INHALANT-INDUCED DEMENTIA
F18280	INHALANT DEPENDENCE WITH INHALANT-INDUCED ANXIETY DISORDER
F18288	INHALANT DEPENDENCE WITH OTHER INHALANT-INDUCED DISORDER
F1829	INHALANT DEPENDENCE WITH UNSPECIFIED INHALANT-INDUCED DISORDER
F1910	OTHER PSYCHOACTIVE SUBSTANCE ABUSE UNCOMPLICATED
F19120	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION UNCOMPLICATED

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F19121	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION DELIRIUM
F19122	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCES
F19129	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION UNSPECIFIED
F1914	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED MOOD DISORDER
F19150	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F19151	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F19159	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F1916	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING AMNESTIC DISORDER
F1917	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING DEMENTIA
F19180	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER
F19181	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SEXUAL DYSFUNCTION
F19182	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SLEEP DISORDER
F19188	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH OTHER PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER
F1919	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH UNSPECIFIED PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER
F1920	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE UNCOMPLICATED
F19220	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION, UNCOMPLICATED
F19221	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION DELIRIUM
F19222	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F19229	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION UNSPECIFIED
F19230	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL UNCOMPLICATED
F19231	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL DELIRIUM
F19232	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE
F19239	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL UNSPECIFIED

Step 2 (history of substance abuse)	
Required quantity: 1	
Look back timeframe: 365 days	
History of Substance Abuse Diagnoses	
F1924	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED MOOD DISORDER
F19250	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F19251	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F19259	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER UNSPECIFIED
F1926	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING AMNESTIC DISORDER
F1927	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING DEMENTIA
F19280	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER
F19281	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SEXUAL DYSFUNCTION
F19282	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SLEEP DISORDER
F19288	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH OTHER PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER
F1929	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH UNSPECIFIED PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER

Step 3 (Texas DFPS maximum recommended dose)				
Required quantity: 1				
TX DFPS Recommended Dosage				
Active Ingredient	Drug (brand)	Initial Dosage	Literature Based Maximum Dosage	FDA Approved Maximum Dosage for Children and Adolescents
AMPHETAMINE/ DEXTROAMPHETAMINE SALTS	ADDERALL® EVEKEO®	Age 3-5 years: 2.5mg/day Age ≥ 6 years: 5-10mg/day	Age 3-5 years: 30mg/day ≥ 6 years and > 50kg: 60mg/day	Approved for children 3 years and older: 40mg/day
DEXMETHYLPHENIDATE	FOCALIN®	Age 3-5 years: 2.5mg/day Age ≥ 6 years: 2.5mg twice daily	Age 3-5 years: 10mg/day Age ≥ 6 years: 50mg/day	Approved for children 6 years and older: 20mg/day
DEXTROAMPHETAMINE	DEXEDRINE® ZENZEDI® PROCENTRA®	Age 3-5 years: 2.5mg/day Age ≥ 6 years: 5mg twice daily	Age 3-5 years: 30mg/day ≥6 years and > 50kg: 60mg/day	Approved for children 3 years and older: 40mg/day
METHAMPHETAMINE	DESOXYN®	5mg daily	N/A	Approved for children 6 years and older: 25mg/day
METHYLPHENIDATE	RITALIN® METHYLIN®	Age 3-5 years: 2.5mg twice daily Age ≥ 6 years: 5mg twice daily	Age 3-5 years: 20mg/day Age ≥ 6 years and ≤ 50kg: 60mg/day Age ≥ 6 years and > 50kg: 100mg/day	Approved for children 6 years and older: 60mg/day

Step 4 (paid claim for another IR stimulant)	
Required quantity: 1	
Look back timeframe: 14 days	
IR Stimulants	
Label Name	GCN
ADDERALL 10MG TABLET	56971
ADDERALL 12.5MG TABLET	29008
ADDERALL 15MG TABLET	29009
ADDERALL 20MG TABLET	56973
ADDERALL 30MG TABLET	56972
ADDERALL 5MG TABLET	56970
ADDERALL 7.5MG TABLET	29007
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG TABLET	56971
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 12.5MG TABLET	29008
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG TABLET	29009
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG TABLET	56973
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG TABLET	56972
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG TABLET	56970
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 7.5MG TABLET	29007
DESOXYN 5MG TABLET	19932
DEXMETHYLPHENIDATE 10MG TABLET	14975
DEXMETHYLPHENIDATE 2.5MG TABLET	14973
DEXMETHYLPHENIDATE 5MG TABLET	14974
DEXTROAMPHETAMINE 10MG TABLET	19880
DEXTROAMPHETAMINE 5MG TABLET	19881
DEXTROAMPHETAMINE 5MG/5ML	99801
EVEKEO 10MG TABLET	19821
EVEKEO 5MG TABLET	19822
FOCALIN 10MG TABLET	14975
FOCALIN 2.5MG TABLET	14973
FOCALIN 5MG TABLET	14974
METHAMPHETAMINE 5MG TABLET	19932
METHYLIN 10MG CHEWABLE TABLET	22684
METHYLIN 10MG/5ML SOLUTION	22686
METHYLIN 2.5MG CHEWABLE TABLET	22682
METHYLIN 5MG CHEWABLE TABLET	22683
METHYLIN 5MG/5ML SOLUTION	22685

Step 4 (paid claim for another IR stimulant)	
Required quantity: 1	
Look back timeframe: 14 days	
IR Stimulants	
Label Name	GCN
METHYLPHENIDATE 10 MG CHEW TB	22684
METHYLPHENIDATE 10MG TABLET	15911
METHYLPHENIDATE 10MG/5ML	22686
METHYLPHENIDATE 2.5 MG CHEW TB	22682
METHYLPHENIDATE 20MG TABLET	15920
METHYLPHENIDATE 5 MG CHEW TB	22683
METHYLPHENIDATE 5MG TABLET	15913
METHYLPHENIDATE 5MG/5ML SOLUTION	22685
PROCENTRA 5MG/5ML SOLUTION	99801
RITALIN 10MG TABLET	15911
RITALIN 20MG TABLET	15920
RITALIN 5MG TABLET	15913
ZENZEDI 10MG TABLET	19880
ZENZEDI 15MG TABLET	19885
ZENZEDI 2.5MG TABLET	34734
ZENZEDI 20MG TABLET	36463
ZENZEDI 30MG TABLET	36464
ZENZEDI 5MG TABLET	19881
ZENZEDI 7.5MG TABLET	34735

Step 6 (amphetamine salts immediate release tablets, dextroamphetamine immediate release tablets, dexamethylphenidate, methylphenidate, Procentra, or Zenzedi)	
Required quantity: 1	
Label Name	GCN
ADDERALL 10MG TABLET	56971
ADDERALL 12.5MG TABLET	29008
ADDERALL 15MG TABLET	29009
ADDERALL 20MG TABLET	56973
ADDERALL 30MG TABLET	56972
ADDERALL 5MG TABLET	56970
ADDERALL 7.5MG TABLET	29007
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG TABLET	56971
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 12.5MG TABLET	29008

Step 6 (amphetamine salts immediate release tablets, dextroamphetamine immediate release tablets, dexamethylphenidate, methylphenidate, Procentra, or Zenzedi)

Required quantity: 1

Label Name	GCN
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG TABLET	29009
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG TABLET	56973
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG TABLET	56972
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG TABLET	56970
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 7.5MG TABLET	29007
DEXMETHYLPHENIDATE 10MG TABLET	14975
DEXMETHYLPHENIDATE 2.5MG TABLET	14973
DEXMETHYLPHENIDATE 5MG TABLET	14974
DEXTROAMPHETAMINE 10MG TABLET	19880
DEXTROAMPHETAMINE 5MG TABLET	19881
DEXTROAMPHETAMINE 5MG/5ML SOLUTION	99801
EVEKEO 10MG TABLET	19821
EVEKEO 5MG TABLET	19822
FOCALIN 10MG TABLET	14975
FOCALIN 2.5MG TABLET	14973
FOCALIN 5MG TABLET	14974
METHYLIN 10MG CHEWABLE TABLET	22684
METHYLIN 10MG/5ML SOLUTION	22686
METHYLIN 2.5MG CHEWABLE TABLET	22682
METHYLIN 5MG CHEWABLE TABLET	22683
METHYLIN 5MG/5ML SOLUTION	22685
METHYLPHENIDATE 10 MG CHEW TB	22684
METHYLPHENIDATE 10MG TABLET	15911
METHYLPHENIDATE 10MG/5ML SOL	22686
METHYLPHENIDATE 2.5 MG CHEW TB	22682
METHYLPHENIDATE 20MG TABLET	15920
METHYLPHENIDATE 5 MG CHEW TB	22683
METHYLPHENIDATE 5MG TABLET	15913
METHYLPHENIDATE 5MG/5ML SOLUTION	22685
PROCENTRA 5MG/5ML SOLUTION	99801
RITALIN 10MG TABLET	15911
RITALIN 20MG TABLET	15920
RITALIN 5MG TABLET	15913
ZENZEDI 10MG TABLET	19880

Step 6 (amphetamine salts immediate release tablets, dextroamphetamine immediate release tablets, dexmethylphenidate, methylphenidate, Procentra, or Zenzedi)

Required quantity: 1

Label Name	GCN
ZENZEDI 15MG TABLET	19885
ZENZEDI 2.5MG TABLET	34734
ZENZEDI 20MG TABLET	36463
ZENZEDI 30MG TABLET	36464
ZENZEDI 5MG TABLET	19881
ZENZEDI 7.5MG TABLET	34735

Step 8 (diagnosis of ADD or ADHD)

Required quantity: 1

Look back timeframe: 730 days

ADD/ADHD Diagnoses

ICD-9 Code	Description
31400	ATTENTION DEFICIT DISORDER WITHOUT MENTION OF HYPERACTIVITY
31401	ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
ICD-10 Code	Description
F900	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, PREDOMINANTLY INATTENTIVE TYPE
F901	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, PREDOMINANTLY HYPERACTIVE TYPE
F902	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, COMBINED TYPE
F908	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, OTHER TYPE
F909	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, UNSPECIFIED TYPE

Step 9 (diagnosis of narcolepsy)

Required diagnosis: 1

Look back timeframe: 730 days

Narcolepsy Diagnoses

ICD-9 Code	Description
34700	NARCOLEPSY WITHOUT CATAPLEXY
34701	NARCOLEPSY WITH CATAPLEXY
34710	NARCOLEPSY IN CONDITIONS CLASSIFIED ELSEWHERE WITHOUT CATAPLEXY

Step 9 (diagnosis of narcolepsy)	
Required diagnosis: 1	
Look back timeframe: 730 days	
Narcolepsy Diagnoses	
ICD-10 Code	Description
34711	NARCOLEPSY IN CONDITIONS CLASSIFIED ELSEWHERE WITH CATAPLEXY
G47419	NARCOLEPSY WITHOUT CATAPLEXY
G47411	NARCOLEPSY WITH CATAPLEXY
G47429	NARCOLEPSY IN CONDITIONS CLASSIFIED ELSEWHERE WITHOUT CATAPLEXY
G47421	NARCOLEPSY IN CONDITIONS CLASSIFIED ELSEWHERE WITH CATAPLEXY

Step 10 (dexmethylphenidate immediate release or methamphetamine)	
Required quantity: 1	
Dexmethylphenidate Immediate Release Drugs/Methamphetamines	
Label Name	GCN
DESOXYN 5MG TABLET	19932
DEXMETHYLPHENIDATE 2.5MG TABLET	14973
DEXMETHYLPHENIDATE 5MG TABLET	14974
DEXMETHYLPHENIDATE 10MG TABLET	14975
FOCALIN 2.5MG TABLET	14973
FOCALIN 5MG TABLET	14974
FOCALIN 10MG TABLET	14975
METHAMPHETAMINE 5MG TABLET	19932



Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD)

ER Formulations

Drugs Requiring Prior Authorization

Drugs Requiring Prior Authorization	
Label Name	GCN
ADDERALL XR 10MG CAPSULE	14635
ADDERALL XR 15MG CAPSULE	17468
ADDERALL XR 20MG CAPSULE	14636
ADDERALL XR 25MG CAPSULE	17469
ADDERALL XR 30MG CAPSULE	14637
ADDERALL XR 5MG CAPSULE	17459
ADZENYS XR-ODT 3.1MG TABLET	40647
ADZENYS XR-ODT 6.3MG TABLET	40648
ADZENYS XR-ODT 9.4MG TABLET	40649
ADZENYS XR-ODT 12.5MG TABLET	40650
ADZENYS XR-ODT 15.7MG TABLET	40653
ADZENYS XR-ODT 18.8MG TABLET	40654
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG EXTENDED-RELEASE CAPSULE	14635
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG EXTENDED-RELEASE CAPSULE	17468
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG EXTENDED-RELEASE CAPSULE	14636
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 25MG EXTENDED-RELEASE CAPSULE	17469
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG EXTENDED-RELEASE CAPSULE	14637
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG EXTENDED-RELEASE CAPSULE	17459
APTENSIO XR 10MG CAPSULE	97234
APTENSIO XR 15MG CAPSULE	97235
APTENSIO XR 20MG CAPSULE	97236
APTENSIO XR 30MG CAPSULE	97237
APTENSIO XR 40MG CAPSULE	97238
APTENSIO XR 50MG CAPSULE	97239
APTENSIO XR 60MG CAPSULE	97240
CONCERTA ER 18MG TABLET	12567
CONCERTA ER 27MG TABLET	17123

Drugs Requiring Prior Authorization	
Label Name	GCN
CONCERTA ER 36MG TABLET	12568
CONCERTA ER 54MG TABLET	12248
DAYTRANA 10MG/9HR PATCH	26801
DAYTRANA 15MG/9HR PATCH	26802
DAYTRANA 20MG/9HR PATCH	26803
DAYTRANA 30MG/9HR PATCH	26804
DEXEDRINE SPANSULE 10MG	19850
DEXEDRINE SPANSULE 15MG	19851
DEXEDRINE SPANSULE 5MG	19852
DEXMETHYLPHENIDATE 10MG EXTENDED RELEASE CAPSULE	24734
DEXMETHYLPHENIDATE 15MG EXTENDED RELEASE CAPSULE	97111
DEXMETHYLPHENIDATE 20MG EXTENDED RELEASE CAPSULE	24735
DEXMETHYLPHENIDATE 30MG EXTENDED RELEASE CAPSULE	28035
DEXMETHYLPHENIDATE 40MG EXTENDED RELEASE CAPSULE	28933
DEXMETHYLPHENIDATE 5MG EXTENDED RELEASE CAPSULE	24733
DEXTROAMPHETAMINE 10MG EXTENDED-RELEASE CAPSULE	19850
DEXTROAMPHETAMINE 15MG EXTENDED-RELEASE CAPSULE	19851
DEXTROAMPHETAMINE 5MG EXTENDED-RELEASE CAPSULE	19852
DYANAVAL XR 2.5MG/ML SUSP	39686
FOCALIN XR 10MG CAPSULE	24734
FOCALIN XR 15MG CAPSULE	97111
FOCALIN XR 20MG CAPSULE	24735
FOCALIN XR 25MG CAPSULE	30305
FOCALIN XR 30MG CAPSULE	28035
FOCALIN XR 35MG CAPSULE	30306
FOCALIN XR 40MG CAPSULE	28933
FOCALIN XR 5MG CAPSULE	24733
METADATE CD 10MG CAPSULE	20384
METADATE CD 20MG CAPSULE	20385
METADATE CD 30MG CAPSULE	20386
METADATE CD 40MG CAPSULE	26734
METADATE CD 50MG CAPSULE	26735
METADATE CD 60MG CAPSULE	26736

Drugs Requiring Prior Authorization	
Label Name	GCN
METADATE ER 20MG TABLET ER	16180
METHYLPHENIDATE 18MG EXTENDED-RELEASE TABLET	12567
METHYLPHENIDATE 20MG EXTENDED-RELEASE CAPSULE	20387
METHYLPHENIDATE 20MG SUSTAINED-RELEASE TABLET	16180
METHYLPHENIDATE 27MG EXTENDED-RELEASE TABLET	17123
METHYLPHENIDATE 30MG EXTENDED-RELEASE CAPSULE	20388
METHYLPHENIDATE 36MG EXTENDED-RELEASE TABLET	12568
METHYLPHENIDATE 40MG EXTENDED-RELEASE CAPSULE	20391
METHYLPHENIDATE 54MG EXTENDED-RELEASE TABLET	12248
METHYLPHENIDATE CD 10MG EXTENDED-RELEASE CAPSULE	20384
METHYLPHENIDATE CD 20MG EXTENDED-RELEASE CAPSULE	20385
METHYLPHENIDATE CD 30MG EXTENDED-RELEASE CAPSULE	20386
METHYLPHENIDATE CD 40MG EXTENDED-RELEASE CAPSULE	26734
METHYLPHENIDATE CD 50MG EXTENDED-RELEASE CAPSULE	26735
METHYLPHENIDATE CD 60MG EXTENDED-RELEASE CAPSULE	26736
METHYLPHENIDATE ER 10 MG TAB	93075
QUILLICHEW ER 20MG CHEW TAB	40289
QUILLICHEW ER 30MG CHEW TAB	40292
QUILLICHEW ER 40MG CHEW TAB	40293
QUILLIVANT XR 25MG/5ML SUSP	33887
RITALIN LA 10MG CAPSULE	21763
RITALIN LA 20MG CAPSULE	20387
RITALIN LA 30MG CAPSULE	20388
RITALIN LA 40MG CAPSULE	20391
VYVANSE 10MG CAPSULE	37674
VYVANSE 20MG CAPSULE	99366
VYVANSE 30MG CAPSULE	98071
VYVANSE 40MG CAPSULE	99367
VYVANSE 50MG CAPSULE	98072
VYVANSE 60MG CAPSULE	99368

Drugs Requiring Prior Authorization	
Label Name	GCN
VYVANSE 70MG CAPSULE	98073



Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD)

ER Formulations Clinical Edit Criteria Logic

1. Is the request for Adzenys XR-ODT or Dyanavel XR suspension?
 Yes – Go to #2
 No – Go to #3
2. Is the client less than (<) 6 years of age?
 Yes – Deny
 No – Go to #4
3. Is the client less than (<) 3 years of age?
 Yes – Deny
 No – Go to #4
4. Does the client have a history of substance abuse in the last 365 days?
 Yes – Deny
 No – Go to #5
5. Is the request for greater than (>) the Texas Department of Family and Protective Services (DFPS) maximum recommended dose?
 Yes – Deny
 No – Go to #6
6. Does the client have a paid claim for another ER stimulant in the past 14 days?
 Yes – Deny
 No – Go to #7
7. Is the client greater than or equal to (\geq) 19 years of age?
 Yes – Go to #8
 No – Approve (365 days)
8. Does the client have a diagnosis of ADD/ADHD in the last 730 days?
 Yes – Approve (365 days)
 No – Go to #9
9. Does the client have a diagnosis of narcolepsy in the last 730 days?
 Yes – Go to #10
 No – Deny


10. Is the request for methylphenidate extended release tablets, methylphenidate sustained release tablets, or dextroamphetamine extended release capsules?
- Yes – Approve (365 days)
 - No – Deny



**Attention Deficit Disorder (ADD) /
Attention Deficit Hyperactivity Disorder
(ADHD)**

**ER Formulations
Clinical Edit Criteria Logic Diagram**

The ER Formulations Clinical Edit Criteria Logic Diagram is shown on the following page.





**Attention Deficit Disorder (ADD) /
Attention Deficit Hyperactivity Disorder
(ADHD)**

ER Formulations

Clinical Edit Criteria Supporting Tables

Step 4 (history of substance abuse)

Required quantity: 1

Look back timeframe: 365 days

For the list of diagnosis codes that pertain to this step, see the **History of Substance Abuse Diagnoses** table in the previous "Supporting Tables" section.

Step 5 (Texas DFPS maximum recommended dose)				
Required quantity: 1				
TX DFPS Recommended Dosage				
Active Ingredient	Drug (brand)	Initial Dosage	Literature Based Maximum Dosage	FDA Approved Maximum Dosage for Children and Adolescents
AMPHETAMINE/ DEXTROAMPHETAMINE SALTS	ADDERALL® XR	Age 3-5 years: 5mg/day Age 6-12 years: 5-10mg/day Age ≥ 13 years: 10mg/day	Age 3-5 years: 30mg/day ≥ 6 years: 60mg/day	Approved for children 6 years and older: 30mg/day
AMPHETAMINE/ DEXTROAMPHETAMINE SALTS	DYANAVEL™ XR	Age ≥ 6 years: 2.5–5mg/day	≥ 6 years: 20mg/day	Approved for children 6 years and older: 20mg/day
AMPHETAMINE/ DEXTROAMPHETAMINE SALTS	ADZENYS XR-ODT™	Age ≥ 6 years: 6.3mg/day	Age 6-12 years: 18.8mg daily Age 13-17 years: 12.5mg daily	Age 6-12 years: 18.8mg daily Age 13-17 years: 12.5mg daily
DESMETHYLPHENIDATE	FOCALIN® XR	Age 3-5 years: 5mg/day Age ≥ 6 years: 5-10mg/day	Age 3-5 years: 10mg/day Age ≥ 6 years: 50mg/day	Approved for children 6 years and older: 30mg/day
DEXTROAMPHETAMINE	DEXEDRINE SPANSULE®	Age 3-5 years: 5mg/day Age ≥ 6 years: 5mg/day	Age 3-5 years: 30mg/day ≥ 6 years and > 50kg: 60mg/day	Approved for children 6 years and older: 40mg/day
LISDEXAMFETAMINE	VYVANSE®	Age 3-5 years: 10mg/day Age ≥ 6 years: 30mg/day	Age 3-5 years: 30mg/day Age ≥ 6 years: 70mg/day	Approved for children 6 years and older: 70mg/day
METHYLPHENIDATE	APTENSIO XR® METADATE® CD RITALIN® LA QUILLICHEW ER™ QUILLIVANT XR®	Age 3-5 years: 10mg/day Age ≥ 6 years: 10 - 20mg/day	Age 3-5 years: 20mg/day Age ≥ 6 years and ≤ 50kg: 60mg/day Age ≥ 6 years and > 50kg: 100mg/day	Approved for children 6 years and older: 60mg/day
	METADATE® ER METHYLIN® ER RITALIN® SR	Age ≥ 3 years: 10mg/day	Age 3-5 years: 20mg/day Age ≥ 6 years and ≤ 50kg: 60mg/day Age ≥ 6 years and > 50kg: 100mg/day	Approved for children 6 years and older: 60mg/day

Step 5 (Texas DFPS maximum recommended dose)				
Required quantity: 1				
TX DFPS Recommended Dosage				
Active Ingredient	Drug (brand)	Initial Dosage	Literature Based Maximum Dosage	FDA Approved Maximum Dosage for Children and Adolescents
	CONCERTA®	Age ≥ 3 years: 18mg/day	Age 3-5 years: 36mg/day Age ≥ 6 years: 108mg/day	Age 6-12 years: 54mg/day Age 13-17 years: lesser of 72mg/day or 2mg/kg/day
	DAYTRANA® TD	Age ≥ 3 years: 10mg/day	Age 3-5 years: 20mg/day Age ≥ 6 years: 30mg/day	Approved for children 6 years and older: 30mg/day

Step 6 (paid claim for another ER stimulant)	
Required quantity: 1	
Look back timeframe: 14 days	
ER Stimulants	
Label Name	GCN
ADDERALL XR 10MG CAPSULE	14635
ADDERALL XR 15MG CAPSULE	17468
ADDERALL XR 20MG CAPSULE	14636
ADDERALL XR 25MG CAPSULE	17469
ADDERALL XR 30MG CAPSULE	14637
ADDERALL XR 5MG CAPSULE	17459
ADZENYS XR-ODT 3.1MG TABLET	40647
ADZENYS XR-ODT 6.3MG TABLET	40648
ADZENYS XR-ODT 9.4MG TABLET	40649
ADZENYS XR-ODT 12.5MG TABLET	40650
ADZENYS XR-ODT 15.7MG TABLET	40653
ADZENYS XR-ODT 18.8MG TABLET	40654
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 10MG EXTENDED-RELEASE CAPSULE	14635
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 15MG EXTENDED-RELEASE CAPSULE	17468
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 20MG EXTENDED-RELEASE CAPSULE	14636
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 25MG EXTENDED-RELEASE CAPSULE	17469
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 30MG EXTENDED-RELEASE CAPSULE	14637
AMPHETAMINE/DEXTROAMPHETAMINE SALTS 5MG EXTENDED-RELEASE CAPSULE	17459
APTENSIO XR 10MG CAPSULE	97234
APTENSIO XR 15MG CAPSULE	97235
APTENSIO XR 20MG CAPSULE	97236
APTENSIO XR 30MG CAPSULE	97237
APTENSIO XR 40MG CAPSULE	97238
APTENSIO XR 50MG CAPSULE	97239
APTENSIO XR 60MG CAPSULE	97240
CONCERTA ER 18MG TABLET	12567
CONCERTA ER 27MG TABLET	17123
CONCERTA ER 36MG TABLET	12568
CONCERTA ER 54MG TABLET	12248
DAYTRANA 10MG/9HR PATCH	26801
DAYTRANA 15MG/9HR PATCH	26802
DAYTRANA 20MG/9HR PATCH	26803
DAYTRANA 30MG/9HR PATCH	26804

Step 6 (paid claim for another ER stimulant)	
Required quantity: 1	
Look back timeframe: 14 days	
ER Stimulants	
Label Name	GCN
DEXEDRINE SPANSULE 10MG	19850
DEXEDRINE SPANSULE 15MG	19851
DEXEDRINE SPANSULE 5MG	19852
DEXMETHYLPHENIDATE 10MG EXTENDED RELEASE CAPSULE	24734
DEXMETHYLPHENIDATE 15MG EXTENDED RELEASE CAPSULE	97111
DEXMETHYLPHENIDATE 20MG EXTENDED RELEASE CAPSULE	24735
DEXMETHYLPHENIDATE 30MG EXTENDED RELEASE CAPSULE	28035
DEXMETHYLPHENIDATE 40MG EXTENDED RELEASE CAPSULE	28933
DEXMETHYLPHENIDATE 5MG EXTENDED RELEASE CAPSULE	24733
DEXTROAMPHETAMINE 10MG EXTENDED-RELEASE CAPSULE	19850
DEXTROAMPHETAMINE 15MG EXTENDED-RELEASE CAPSULE	19851
DEXTROAMPHETAMINE 5MG EXTENDED-RELEASE CAPSULE	19852
DYANAVAL 2.5MG/ML SUSP	39686
FOCALIN XR 10MG CAPSULE	24734
FOCALIN XR 15MG CAPSULE	97111
FOCALIN XR 20MG CAPSULE	24735
FOCALIN XR 25MG CAPSULE	30305
FOCALIN XR 30MG CAPSULE	28035
FOCALIN XR 35MG CAPSULE	30306
FOCALIN XR 40MG CAPSULE	28933
FOCALIN XR 5MG CAPSULE	24733
METADATE CD 10MG CAPSULE	20384
METADATE CD 20MG CAPSULE	20385
METADATE CD 30MG CAPSULE	20386
METADATE CD 40MG CAPSULE	26734
METADATE CD 50MG CAPSULE	26735
METADATE CD 60MG CAPSULE	26736
METADATE ER 20MG TABLET ER	16180
METHYLPHENIDATE 18MG EXTENDED-RELEASE TABLET	12567
METHYLPHENIDATE 20MG EXTENDED-RELEASE CAPSULE	20387

Step 6 (paid claim for another ER stimulant)	
Required quantity: 1	
Look back timeframe: 14 days	
ER Stimulants	
Label Name	GCN
METHYLPHENDIATE 20MG EXTENDED-RELEASE TABLET	16180
METHYLPHENIDATE 27MG EXTENDED-RELEASE TABLET	17123
METHYLPHENIDATE 30MG EXTENDED-RELEASE CAPSULE	20388
METHYLPHENIDATE 36MG EXTENDED-RELEASE TABLET	12568
METHYLPHENIDATE 40MG EXTENDED-RELEASE CAPSULE	20391
METHYLPHENIDATE 54MG EXTENDED-RELEASE TABLET	12248
METHYLPHENIDATE CD 10MG EXTENDED-RELEASE CAPSULE	20384
METHYLPHENIDATE CD 20MG EXTENDED-RELEASE CAPSULE	20385
METHYLPHENIDATE CD 30MG EXTENDED-RELEASE CAPSULE	20386
METHYLPHENIDATE CD 40MG EXTENDED-RELEASE CAPSULE	26734
METHYLPHENIDATE CD 50MG EXTENDED-RELEASE CAPSULE	26735
METHYLPHENIDATE CD 60MG EXTENDED-RELEASE CAPSULE	26736
METHYLPHENIDATE ER 10 MG TAB	93075
QUILLICHEW ER 20MG CHEW TAB	40289
QUILLICHEW ER 30MG CHEW TAB	40292
QUILLICHEW ER 40MG CHEW TAB	40293
QUILLIVANT XR 25MG/5ML SUSP	33887
RITALIN LA 10MG CAPSULE	21763
RITALIN LA 20MG CAPSULE	20387
RITALIN LA 30MG CAPSULE	20388
RITALIN LA 40MG CAPSULE	20391
VYVANSE 10MG CAPSULE	37674
VYVANSE 20MG CAPSULE	99366
VYVANSE 30MG CAPSULE	98071
VYVANSE 40MG CAPSULE	99367
VYVANSE 50MG CAPSULE	98072
VYVANSE 60MG CAPSULE	99368
VYVANSE 70MG CAPSULE	98073

Step 8 (diagnosis of ADD or ADHD)**Required quantity: 1****Look back timeframe: 730 days**

For the list of diagnoses that pertain to this step, see the [ADD/ADHD Diagnoses](#) table in the previous "Supporting Tables" section.

Step 9 (diagnosis of narcolepsy)**Required diagnosis: 1****Look back timeframe: 730 days**

For the list of diagnoses that pertain to this step, see the [Narcolepsy Diagnoses](#) table in the previous "Supporting Tables" section.

Step 10 (methylphenidate extended release tablets, methylphenidate sustained release tablets, or dextroamphetamine extended release capsules)**Required quantity: 1**

Label Name	GCN
APTENSIO XR 10MG CAPSULE	97234
APTENSIO XR 15MG CAPSULE	97235
APTENSIO XR 20MG CAPSULE	97236
APTENSIO XR 30MG CAPSULE	97237
APTENSIO XR 40MG CAPSULE	97238
APTENSIO XR 50MG CAPSULE	97239
APTENSIO XR 60MG CAPSULE	97240
CONCERTA ER 18MG TABLET	12567
CONCERTA ER 27MG TABLET	17123
CONCERTA ER 36MG TABLET	12568
CONCERTA ER 54MG TABLET	12248
DAYTRANA 10MG/9HR PATCH	26801
DAYTRANA 15MG/9HR PATCH	26802
DAYTRANA 20MG/9HR PATCH	26803
DAYTRANA 30MG/9HR PATCH	26804
DEXEDRINE SPANSULE 5MG	19852
DEXEDRINE SPANSULE 10MG	19850
DEXEDRINE SPANSULE 15MG	19851
DEXTROAMPHETAMINE 5MG EXTENDED-RELEASE CAPSULE	19852

Step 10 (methylphenidate extended release tablets, methylphenidate sustained release tablets, or dextroamphetamine extended release capsules)	
Required quantity: 1	
Label Name	GCN
DEXTROAMPHETAMINE 10MG EXTENDED-RELEASE CAPSULE	19850
DEXTROAMPHETAMINE 15MG EXTENDED-RELEASE CAPSULE	19851
METADATE CD 10MG CAPSULE	20384
METADATE CD 20MG CAPSULE	20385
METADATE CD 30MG CAPSULE	20386
METADATE CD 40MG CAPSULE	26734
METADATE CD 50MG CAPSULE	26735
METADATE CD 60MG CAPSULE	26736
METADATE ER 20MG TABLET ER	16180
METHYLPHENIDATE 18MG EXTENDED-RELEASE TABLET	12567
METHYLPHENIDATE 20MG EXTENDED-RELEASE CAPSULE	20387
METHYLPHENIDATE 20MG SUSTAINED-RELEASE TABLET	16180
METHYLPHENIDATE 27MG EXTENDED-RELEASE TABLET	17123
METHYLPHENIDATE 30MG EXTENDED-RELEASE CAPSULE	20388
METHYLPHENIDATE 36MG EXTENDED-RELEASE TABLET	12568
METHYLPHENIDATE 40MG EXTENDED-RELEASE CAPSULE	20391
METHYLPHENIDATE 54MG EXTENDED-RELEASE TABLET	12248
METHYLPHENIDATE CD 10MG EXTENDED-RELEASE CAPSULE	20384
METHYLPHENIDATE CD 20MG EXTENDED-RELEASE CAPSULE	20385
METHYLPHENIDATE CD 30MG EXTENDED-RELEASE CAPSULE	20386
METHYLPHENIDATE CD 40MG EXTENDED-RELEASE CAPSULE	26734
METHYLPHENIDATE CD 50MG EXTENDED-RELEASE CAPSULE	26735
METHYLPHENIDATE CD 60MG EXTENDED-RELEASE CAPSULE	26736
METHYLPHENIDATE ER 10 MG TAB	93075
QUILLICHEW ER 20MG CHEW TAB	40289
QUILLICHEW ER 30MG CHEW TAB	40292
QUILLICHEW ER 40MG CHEW TAB	40293
QUILLIVANT XR 25MG/5ML SUSP	33887

Step 10 (methylphenidate extended release tablets, methylphenidate sustained release tablets, or dextroamphetamine extended release capsules)	
Required quantity: 1	
Label Name	GCN
RITALIN LA 10MG CAPSULE	21763
RITALIN LA 20MG CAPSULE	20387
RITALIN LA 30MG CAPSULE	20388
RITALIN LA 40MG CAPSULE	20391



**Attention Deficit Disorder (ADD) /
Attention Deficit Hyperactivity Disorder
(ADHD)
Non-stimulant Formulations (Except
Clonidine ER)
Drugs Requiring Prior Authorization**

Drugs Requiring Prior Authorization	
Label Name	GCN
GUANFACINE HCL ER 1MG TABLET	27576
GUANFACINE HCL ER 2MG TABLET	27578
GUANFACINE HCL ER 3MG TABLET	27579
GUANFACINE HCL ER 4MG TABLET	27582
INTUNIV ER 1MG TABLET	27576
INTUNIV ER 2MG TABLET	27578
INTUNIV ER 3MG TABLET	27579
INTUNIV ER 4MG TABLET	27582
STRATTERA 100MG CAPSULE	26539
STRATTERA 10MG CAPSULE	18776
STRATTERA 18MG CAPSULE	18777
STRATTERA 25MG CAPSULE	18778
STRATTERA 40MG CAPSULE	18779
STRATTERA 60MG CAPSULE	18781
STRATTERA 80MG CAPSULE	26538



**Attention Deficit Disorder (ADD) /
Attention Deficit Hyperactivity Disorder
(ADHD)**

**Non-stimulant Formulations (Except
Clonidine ER)**

Clinical Edit Criteria Logic


1. Is the client less than (<) 6 years of age?
 Yes – Deny
 No – Go to #2
2. Is the request for greater than (>) 2 units per day?
 Yes – Deny
 No – Go to #3
3. Is the client greater than or equal to (\geq) 19 years of age?
 Yes – Go to #4
 No – Approve (365 days)
4. Does the client have a diagnosis of ADD/ADHD in the last 730 days?
 Yes – Approve (365 days)
 No – Deny



Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD)

Non-stimulant Formulations (Except Clonidine ER)

Clinical Edit Criteria Logic Diagram





**Attention Deficit Disorder (ADD) /
Attention Deficit Hyperactivity Disorder
(ADHD)
Non-stimulant Formulations (Except
Clonidine ER)
Clinical Edit Criteria Supporting Tables**

Step 4 (diagnosis of ADD or ADHD)

Required quantity: 1

Look back timeframe: 730 days

For the list of diagnoses that pertain to this step, please see the **ADD/ADHD Diagnoses** table in a previous "Supporting Tables" section.



**Attention Deficit Disorder (ADD) /
Attention Deficit Hyperactivity Disorder
(ADHD)**

**Clonidine ER
Drugs Requiring Prior Authorization**

Drugs Requiring Prior Authorization	
Label Name	GCN
CLONIDINE HCL ER 0.1MG TABLET	29139



**Attention Deficit Disorder (ADD) /
Attention Deficit Hyperactivity Disorder
(ADHD)**


**Clonidine ER
Clinical Edit Criteria Logic**

1. Is the client less than (<) 6 years of age?
 Yes - Deny
 No - Go to #2
2. Is the request for greater than (>) 4 units per day?
 Yes - Deny
 No - Go to #3
3. Is the client greater than or equal to (\geq) 19 years of age?
 Yes - Go to #4
 No - Approve (365 days)
4. Does the client have a diagnosis of ADD/ADHD in the last 730 days?
 Yes - Approve (365 days)
 No - Deny



Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD)

Clonidine ER Clinical Edit Criteria Logic Diagram





**Attention Deficit Disorder (ADD) /
Attention Deficit Hyperactivity Disorder
(ADHD)**

Clonidine ER

Clinical Edit Criteria Supporting Tables

Step 4 (diagnosis of ADD or ADHD)

Required quantity: 1

Look back timeframe: 730 days

For the list of diagnoses that pertain to this step, see the **ADD/ADHD Diagnoses** table in a previous "Supporting Tables" section.



Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD)

Clinical Edit Criteria References

1. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; 2015. Available at www.clinicalpharmacology.com. Accessed on March 4, 2016.
2. Micromedex [online database]. Available at www.micromedexsolutions.com. Accessed on March 4, 2016.
3. The American Academy of Pediatrics. Implementing the key action statements: An algorithm and explanation for process of care for the evaluation, diagnosis, treatment and monitoring of ADHD in children and adolescents. November 1, 2011. Available at <http://pediatrics.aappublications.org/content/suppl/2011/10/11/ped.s.2011-2654.DC1/zpe611117822p.pdf>.
4. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN Report: Emergency department visits involving attention deficit/hyperactivity disorder stimulant medications. Rockville, MD. January 24, 2013.
5. Texas Department of Family and Protective Services and The University of Texas at Austin College of Pharmacy. Psychotropic Medication Utilization Parameters for Children and Youth in Foster Care (5th Version). March 2016 (Updated July 2016).
6. 2015 ICD-9-CM Diagnosis Codes. 2015. Available at www.icd9data.com. Accessed on April 3, 2015.
7. 2015 ICD-10-CM Diagnosis Codes. 2015. Available at www.icd10data.com. Accessed on April 3, 2015.
8. American Medical Association data files. 2015 ICD-9-CM Diagnosis Codes. Available at www.commerce.ama-assn.org.
9. American Medical Association data files. 2015 ICD-10-CM Diagnosis Codes. Available at www.commerce.ama-assn.org.
10. Aptensio XR Prescribing Information. Coventry, RI. Rhodes Pharmaceuticals L.P. April 2015.
11. Concerta Prescribing Information. Titusville, NJ. Janssen Pharmaceuticals, Inc. December 2013.

12. Daytrana Prescribing Information. Miami, FL. Noven Therapeutics, LLC. August 2015.
13. Evekeo Prescribing Information. Atlanta, GA. Arbor Pharmaceuticals, LLC. May 2015.
14. Focalin Prescribing Information. East Hanover, NJ. Novartis Pharmaceuticals Corporation. April 2015.
15. Focalin XR Prescribing Information. East Hanover, NJ. Novartis Pharmaceuticals Corporation. June 2015.
16. Intuniv Prescribing Information. Lexington, MA. Shire US Inc. December 2015.
17. Ritalin and Ritalin-SR Prescribing Information. East Hanover, NJ. Novartis Pharmaceuticals Corporation. April 2015.
18. Ritalin LA Prescribing Information. East Hanover, NJ. Novartis Pharmaceuticals Corporation. July 2015.
19. Quillichew ER Prescribing Information. New York, NY. Pfizer, Inc. December 2015.
20. Quillivant XR Prescribing Information. New York, NY. Pfizer, Inc. February 2015.
21. Strattera Prescribing Information. Indianapolis, IN. Eli Lilly and Company. April 2015.
22. Vyvanse Prescribing Information. Lexington, MA. Shire US Inc. December 2015.
23. Zenzedi Prescribing Information. Atlanta, GA. Arbor Pharmaceuticals, LLC. January 2014.
24. Adzenys XR-ODT Prescribing Information. Grand Prairie, TX. Neos Therapeutics, Inc. January 2016.

Publication History

The Publication History records the publication iterations and revisions to this document. Notes for the *most current revision* are also provided in the **Revision Notes** on the first page of this document.

Publication Date	Notes
07/15/2013	Initial publication
04/16/2014	<ul style="list-style-type: none"> Updated ER and NS written criteria
05/02/2014	<ul style="list-style-type: none"> Removed Clonidine ER from the non-stimulant edit and built a separate edit allowing for 4 units/day In the Clonidine ER section, amended Step 2 in the criteria logic to "Is the request for greater than (>) 4 units per day?" In the Clonidine ER section, amended Step 2 in the criteria logic diagram to "Is the request for greater than (>) 4 units per day?"
06/20/2014	<ul style="list-style-type: none"> Revised step 3 in the IR Formulations clinical edit criteria logic section from "FDA maximum recommended dose" to "Texas Department of Family and Protective Services (DFPS) maximum recommended daily dose" Revised step 3 in the IR Formulations clinical edit criteria logic diagram from "FDA" to "TX DFPS" In the IR Formulations section, added GCNs for dexamethylphenidate and methylphenidate to the supporting table for step 6 to reflect new age guidelines In the IR Formulations section, added the GCN for methamphetamine to the supporting table for step 11 Revised step 3 in the ER Formulations clinical edit criteria logic from "FDA maximum recommended dose" to "Texas Department of Family and Protective Services (DFPS) maximum recommended daily dose" Revised step 3 in the ER Formulations clinical edit criteria logic diagram from "FDA" to "TX DFPS"
02/27/2015	<ul style="list-style-type: none"> Revised approval duration for Step 8 in the clinical edit logic and diagram for IR formulations Revised approval duration for Step 6 in the clinical edit logic and diagram for ER formulations Revised approval duration for Step 4 in the clinical edit logic and diagram for Non-Stimulant Agents (including clonidine ER)
03/27/2015	<ul style="list-style-type: none"> Removed Step 8 in the clinical edit logic and diagram for IR formulations Removed Step 6 in the clinical edit logic and diagram for ER formulations Removed Step 4 in the clinical edit logic and diagram for Non-Stimulant Agents (including clonidine ER)

Publication Date	Notes
04/06/2015	<ul style="list-style-type: none"> Added GCN for Vyvanse 10mg
04/06/2015	<ul style="list-style-type: none"> Updated to include ICD-10s
09/02/2015	<ul style="list-style-type: none"> Updated to include Evekeo GCNs
10/07/2015	<ul style="list-style-type: none"> Updated to include Texas DFPS maximum dosage recommendations for ER formulations
11/04/2015	<ul style="list-style-type: none"> Updated the Texas DFPS dosage recommendation charts
12/22/2015	<ul style="list-style-type: none"> Updated the approval duration on step 3 of the Clonidine ER criteria logic
02/01/2016	<ul style="list-style-type: none"> Added Aptensio XR GCNs
05/19/2016	<ul style="list-style-type: none"> Updated IR Drugs Requiring PA, page 3 Updated Table 3 (added Zenzedi), page 21 Reviewed and updated Table 4, page 22 Reviewed and updated Table 6, page 23 Updated ER Drugs Requiring PA, page 27 Updated Table 3 (Added Quillichew ER and Quillivant XR), page 34 Reviewed and updated Table 4, page 35 Reviewed and updated Table 8, page 38 Updated Clinical References, page 49
07/21/2016	<ul style="list-style-type: none"> Updated TX DFPS Recommended Dosing Tables, page 21 and 34 Added GCNs for Adzenys XR-ODT tablets to 'Drugs Requiring PA', page 27 and Table 4, page 36 Updated References, page 50